Recent

% | $
Quotes you view appear here for quick access.

Arena Pharmaceuticals, Inc. Message Board

  • sauve9 sauve9 Oct 1, 2013 12:17 PM Flag

    Arena priced like a Chinese generic

    Do what I did.
    Get a stock screener and look for billion dollar market cap drug companies with a new & novel product on the market.
    There is Arena and EVERYTHING ELSE IS CHINESE.
    Then you decide.

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • BELVIQ is safe, effective, well tolerated !
      Henry MD

      Sentiment: Strong Buy

    • hedge_risk@ymail.com hedge_risk Oct 1, 2013 12:18 PM Flag

      Sauve ,,, don't overvalue new and novel. Provenge was/is new and novel, too.

      • 5 Replies to hedge_risk
      • That is where the "Then you decide" comes in.
        Common sense is your best starting point
        Here is your list of FDA approved new and novel from June 2012 to present
        TIVICAY DOLUTEGRAVIR SODIUM 1   P  VIIV HLTHCARE 08/12/2013 
        (NDA # 204790)
        GILOTRIF
        (NDA # 201292)
        AFATINIB DIMALEATE 1 P BOEHRINGER INGELHEIM 7/12/2013
        BREO ELLIPTA
        (NDA # 204275)
        FLUTICASONE FUROATE; VILANTEROL TRIFENATATE 1 S GLAXO GRP LTD 5/10/2013
        XOFIGO
        (NDA # 203971)
        RADIUM RA-223 DICHLORIDE 1 P BAYER HLTHCARE 5/15/2013
        TAFINLAR
        (NDA # 202806)
        DABRAFENIB MESYLATE 1 S GLAXOSMITHKLINE 5/29/2013
        MEKINIST
        (NDA # 204114)
        TRAMETINIB DIMETHYL SULFOXIDE 1 S GLAXOSMITHKLINE LLC 5/29/2013
        LYMPHOSEEK KIT
        (NDA # 202207)
        TECHNETIUM TC-99M TILMANOCEPT 1 S NAVIDEA BIOPHARMS 3/13/2013
        DOTAREM
        (NDA # 204781)
        GADOTERATE MEGLUMINE 1 P GUERBET 3/20/2013
        TECFIDERA
        (NDA # 204063)
        DIMETHYL FUMARATE 1 S BIOGEN IDEC INC 3/27/2013
        INVOKANA
        (NDA # 204042)
        CANAGLIFLOZIN 1 S JANSSEN PHARMS 3/29/2013
        POMALYST
        (NDA # 204026)
        POMALIDOMIDE 1 S CELGENE 2/8/2013
        OSPHENA
        (NDA # 203505)
        OSPEMIFENE 1 S SHIONOGI INC 2/26/2013
        NESINA
        (NDA # 022271)
        ALOGLIPTIN BENZOATE 1 S TAKEDA PHARMS USA 1/25/2013
        OSENI
        (NDA # 022426)
        ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE 1 S TAKEDA PHARMS USA 1/25/2013
        KAZANO
        (NDA # 203414)
        ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDE 1 S TAKEDA PHARMS USA 1/25/2013
        KYNAMRO
        (NDA # 203568)
        MIPOMERSEN SODIUM 1 S GENZYME CORP 1/29/2013
        SIGNIFOR
        (NDA # 200677)
        PASIREOTIDE DIASPARTATE 1 S NOVARTIS 12/14/2012
        ICLUSIG
        (NDA # 203469)
        PONATINIB HYDROCHLORIDE 1 P, O ARIAD 12/14/2012
        GATTEX KIT
        (NDA # 203441)
        TEDUGLUTIDE RECOMBINANT 1 S, O NPS PHARMS INC 12/21/2012
        JUXTAPID
        (NDA # 203858)
        LOMITAPIDE MESYLATE 1 S AEGERION 12/21/2012
        ELI

        Sentiment: Strong Buy

      • Provenge's market is no where near the size of Belviq's. 110,000,000 obese defined as 30% or higher BMI... The old diet and exercise has not worked for any of them and obesity is going up. Surgery is to evasive and I for one have been against it for anyone....

        200 bucks a month to get healthy for 2 years. 100,000 for 3 treatments that give you a small chance to extend your life for a few more years.... Hmmmmmm... not the same thing.

      • Provenge, really? Is that the only comparison you have for this?

      • and it was also far too expensive relative to it's effectiveness to be a big success. This is a very different situation - not just new and novel, but easily worth the price of a prescription, vastly larger market, etc.
        I sold my DNDN over $50

        Sentiment: Strong Buy

      • provenge is a different animal..cost of over 90k per year for a few months of life extention...Belviq helps one lose weight and has diabetic benefits at 225 per month with up to 50% insurance coverage by YE per Eisai

 
ARNA
1.630.00(0.00%)Aug 26 4:00 PMEDT